# Long-Term Risks of Semaglutide: All Injectable & Oral Formulations **Prepared by:** Pedro Cheung MD **Last Updated:** May 2026 **Evidence Base:** SELECT, FLOW, SOUL, SUSTAIN, PIONEER, STEP, OASIS trial programs; FDA prescribing labels (2024–2026); EMA/MHRA/WHO safety communications (2025–2026); peer-reviewed meta-analyses and systematic reviews (2023–2026) --- ## Background: Formulations & FDA-Approved Indications Semaglutide is a **GLP-1 (glucagon-like peptide-1) receptor agonist** manufactured by Novo Nordisk. It is the only GLP-1 agonist available in both injectable and oral forms, and the only agent in this class with cardiovascular outcomes data across all four formulations. As of January 2026, the FDA has approved **four distinct semaglutide products**, including the newly approved **Wegovy® pill** — the first oral GLP-1 receptor agonist approved for chronic weight management anywhere in the world. ### The Four Brands — Key Differences |Brand|Formulation|Route|Primary Indication|Doses| |---|---|---|---|---| |**Ozempic®**|Semaglutide injection|Subcutaneous, once weekly|Type 2 diabetes; CV risk reduction; CKD in T2DM|0.5 mg, 1 mg, 2 mg| |**Wegovy® (injection)**|Semaglutide injection|Subcutaneous, once weekly|Chronic weight management; CV risk reduction; MASH (F2–F3); ≥12 years|0.25→2.4 mg (escalation); HD 7.2 mg| |**Wegovy® (pill)**|Semaglutide tablet|Oral, once daily|Chronic weight management; CV risk reduction|1.5→25 mg (escalation)| |**Rybelsus®**|Semaglutide tablet|Oral, once daily|Type 2 diabetes|3 mg, 7 mg, 14 mg| **Wegovy® pill (semaglutide 25 mg tablet)** — FDA approved December 22, 2025; US launch January 2026. The first oral GLP-1 approved for obesity treatment in the US.[^WegovyPill-approval] **Critical dosing notes:** - Wegovy injection 2.4 mg is a **higher dose** than Ozempic 0.5–2 mg and they are **not interchangeable.** - Wegovy pill 25 mg daily ≠ Rybelsus 14 mg daily — different indications, different dose ceiling, meaningfully different weight loss outcomes. - **Coadministration of any two semaglutide-containing products is contraindicated.**[^Ozempic-label][^Wegovy-label][^Rybelsus-label] **Oral semaglutide absorption requirements (both Rybelsus AND Wegovy pill):** Both oral formulations use the same SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption-enhancing technology and require identical fasting protocols: taken **on an empty stomach** in the morning with **no more than 120 mL (4 oz) of plain water only**, **≥30 minutes before** the first food, drink, or other oral medication of the day. Tablets must be swallowed whole — do not crush, cut, chew, or dissolve. Failure to follow these instructions significantly reduces bioavailability (~1% oral bioavailability under optimal conditions).[^StatPearls][^WegovyPill-dosing] --- ## 1. GASTROINTESTINAL COMPLICATIONS (Most Common) ### Incidence Across Formulations GI adverse events are the dominant side-effect class for all semaglutide formulations. Rates differ meaningfully by dose and route:[^Feier][^Sillassen2025][^OASIS4] |GI Adverse Event|Ozempic 0.5–1 mg (T2DM)|Wegovy injection 2.4 mg (Obesity)|Wegovy pill 25 mg (Obesity)|Rybelsus 14 mg (T2DM)| |---|---|---|---|---| |**Nausea**|~15–20%|**44%**|included in 74% any GI|~15%| |**Diarrhea**|~8–13%|~30%|included in 74% any GI|~10%| |**Vomiting**|~5–6%|~24%|included in 74% any GI|~5–6%| |**Constipation**|~3–5%|~24%|included in 74% any GI|~3%| |**Any GI event**|~30–40%|~56%|**74%** vs 42% placebo|~35%| **Wegovy pill GI burden is the highest of all formulations.** In OASIS 4, gastrointestinal adverse events were reported in **74.0% of oral semaglutide 25 mg patients vs. 42.2% with placebo** — a higher rate than even injectable Wegovy 2.4 mg in STEP trials (~56%). This is likely attributable to the daily dosing schedule (continuous rather than once-weekly exposure peaks) and the high semaglutide dose required to overcome poor oral bioavailability.[^OASIS4][^Wharton] Nausea is the most prevalent adverse event with injectable Wegovy — reported in **nearly half of patients** during titration.[^StatPearls] Oral semaglutide shows similar GI profiles to injectable at equivalent exposure, with daily dosing meaning **more sustained, lower-peak GI exposure** than weekly injection.[^Weiskirchen] ### Important 2025 Label Updates The FDA added a **"Severe Gastrointestinal Adverse Reactions"** warning to both Ozempic (October 2025) and Wegovy (October 2025) prescribing information, noting rates of severe GI events of **4.1% (Wegovy) and ~0.4–0.8% (Ozempic)** vs. 0.9% and 0% placebo, respectively. Postmarketing reports include **ileus, intestinal obstruction, severe constipation including fecal impaction.**[^GLP1-regulatory] **All three formulations now include:** "Not recommended in patients with severe gastroparesis."[^Ozempic-label][^Wegovy-label][^Rybelsus-label] ### Discontinuation In SELECT (Wegovy 2.4 mg, 39.8-month mean follow-up), **16.6% of semaglutide patients vs. 8.2% of placebo patients permanently discontinued** the drug, with GI disorders driving 10.0% vs. 2.0% of discontinuations.[^Kushner] Real-world data confirm high 1-year discontinuation rates of **20–50%**, primarily GI-driven.[^Thomsen] ### Clinical Recommendation Gradual dose titration, small frequent meals, avoidance of high-fat foods during escalation, and antiemetics as needed. For oral semaglutide, reinforce the strict fasting/water requirement at every visit. --- ## 2. LEAN MUSCLE MASS LOSS — Updated 2025–2026 Evidence This section has been substantially expanded to reflect the growing body of evidence on semaglutide's impact on body composition. ### The Core Finding Semaglutide induces weight loss that includes both **fat mass and lean (muscle) mass loss.** The key question is: how much muscle is lost, is it clinically meaningful, and is it reversible? ### Quantifying Lean Mass Loss with Semaglutide **Meta-analysis (Karakasis et al., 2024, 22 RCTs, n=2,258):** GLP-1 RAs including semaglutide reduced total body weight (MD −3.55 kg), fat mass (MD −2.95 kg), and lean mass (MD −0.86 kg). Lean mass loss comprised approximately **25% of total weight lost.** Critically, the relative lean mass percentage (lean mass as a fraction of total body weight) was **not significantly reduced**, suggesting body composition ratios were preserved even as absolute lean mass fell.[^Karakasis] **However, a key comparative finding (Ryan, 2025):** Of weight lost with **semaglutide, approximately 45% comes from lean mass**, compared to 25% with tirzepatide.[^Ryan] This higher lean-to-fat loss ratio for semaglutide vs. tirzepatide is a consistent finding across reviews and may relate to the dual GIP receptor activation of tirzepatide providing additional metabolic benefits. **SEMALEAN Study (Alissou et al., 2025) — prospective, DXA-measured, n=106, Wegovy 2.4 mg):** At 7 months, lean mass declined by −3 kg but **stabilized thereafter.** At 12 months, handgrip strength improved significantly (+4.5 kg), and the prevalence of **sarcopenic obesity fell from 49% to 33%.** REE (resting energy expenditure) normalized to lean mass increased from month 7 to month 12, suggesting metabolic adaptation. These are reassuring findings suggesting functional muscle improvement despite modest absolute lean mass loss.[^SEMALEAN] **Real-world compounded semaglutide body composition (Chun et al., 2025, n=94):** After 3 months, patients lost 4.57% body weight with a small loss in absolute lean mass (−1.43 kg) and skeletal muscle mass (−0.88 kg). **As a proportion of total body weight, however, fat mass decreased while lean muscle mass percentage increased** — suggesting favorable compositional shift.[^Chun] **CT-based AI body composition (Nelson et al., 2024, n=241):** Semaglutide-associated weight loss was linked to decreases in visceral fat, subcutaneous fat, and muscle area, but also to **improvements in liver attenuation** (reduced hepatic steatosis). Patients who gained weight on semaglutide showed decreased muscle attenuation (worse muscle quality), underscoring that weight gain on the drug is metabolically unfavorable.[^Nelson] **Muscle mass changes: adaptive or maladaptive?** MRI-based studies suggest skeletal muscle volume reductions with GLP-1 RAs are largely **adaptive** — proportional to what would be expected given aging, disease status, and degree of weight loss achieved. Improvements in insulin sensitivity and reductions in **muscle fat infiltration** likely contribute to improved muscle quality, reducing the risk of functional loss.[^Neeland][^Linge] **Animal/mechanistic data (Jeromson et al., 2025):** In obese mice, semaglutide and matched caloric restriction reduced muscle size and strength to a **similar extent** — suggesting muscle loss may be driven by caloric deficit rather than a direct drug effect. Importantly, after treatment discontinuation, lean mass and skeletal muscle **recovered to baseline levels** in both groups.[^Jeromson] ### Clinical Implications by Risk Group |Patient Profile|Risk Level|Key Concern| |---|---|---| |**Healthy younger adults**|Low|Lean mass proportion preserved; functional outcome likely favorable| |**Adults 50–65**|Moderate|Monitor with resistance exercise; ensure protein sufficiency| |**Adults ≥65 / frailty**|**High**|Accelerated sarcopenia; risk of falls, functional decline| |**Pre-existing sarcopenic obesity**|**High**|Careful selection; exercise + protein essential| |**Patients with low muscle baseline**|High|Baseline body composition assessment advised| ### Mitigation Strategies (Evidence-Based) **1. Resistance Exercise Training** The strongest intervention. Supervised resistance training >10 weeks can produce ~3 kg lean mass gain and ~25% strength improvement, substantially offsetting semaglutide-related lean mass loss. Aerobic-exercise combinations further support weight loss maintenance on GLP-1 therapy.[^Locatelli] **2. Adequate Protein Intake** Target ≥1.2–1.6 g/kg/day of high-quality protein. Up to 40% of total weight loss can come from fat-free mass without protein optimization. Specific nutrients with emerging evidence include branched-chain amino acids (BCAAs), creatine, leucine, omega-3 fatty acids, and vitamin D.[^Chavez] **3. Ketogenic or Protein-Sparing Diets** Preliminary evidence suggests combining tirzepatide (analogous data, likely applicable to semaglutide) with a low-energy ketogenic diet better preserves fat-free mass vs. standard low-calorie diet. Further study needed.[^Ryan] **4. Emerging Pharmacological Approaches** **Bimagrumab** (anti-ActRII monoclonal antibody) blocks activin/myostatin signaling and has demonstrated: +10% lean mass while simultaneously decreasing fat mass in obese animal models; in combination with semaglutide, superior fat loss while **preserving lean mass.** Phase 2 trials in humans are ongoing.[^Nunn][^Stefanakis] Other pipeline agents: trevogrumab, garetosmab (myostatin-activin pathway inhibitors). ### Bone Health Caution Over 25% of total weight lost with incretin receptor agonists typically comes from fat-free mass, including **skeletal muscle AND bone.** Loss of muscle and bone can compromise physical function, metabolic rate, and overall health — particularly in older adults. The myostatin-activin-follistatin system plays a crucial role in muscle and bone maintenance during negative energy balance.[^Stefanakis] --- ## 3. THYROID CANCER (Medullary) — Boxed Warning ### FDA Black Box Warning (All Formulations)[^Ozempic-label][^Wegovy-label][^Rybelsus-label] In mice and rats, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas). Human relevance is **unknown.** **Contraindicated in patients with:** - Personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ### Incidence In a systematic review (10 RCTs, n=14,550, 7,830 receiving semaglutide), the incidence of thyroid cancer in semaglutide-treated patients was **less than 1%**, with no significant increase vs. comparators.[^Feier] Postmarketing cases of MTC in patients treated with liraglutide (another GLP-1 RA) have been reported; data are insufficient to establish or exclude a causal relationship for semaglutide.[^Ozempic-label] ### Clinical Recommendation - Routine calcitonin monitoring or thyroid ultrasound **is not recommended** as standard practice. - Counsel patients to report neck masses, hoarseness, dysphagia, or dyspnea. - If calcitonin is measured and elevated >50 ng/L, further evaluation is warranted. --- ## 4. OPHTHALMIC COMPLICATIONS ### 4A. Diabetic Retinopathy — Injectable Semaglutide **SUSTAIN 6 (2-year CV outcomes trial, T2DM, Ozempic):** Diabetic retinopathy complications occurred in **3.0% semaglutide vs. 1.8% placebo.** Absolute risk increase was substantially greater in patients with **pre-existing diabetic retinopathy** (semaglutide 8.2% vs. placebo 5.2%) vs. no baseline retinopathy (0.7% vs. 0.4%).[^Ozempic-label][^Rybelsus-label] **Pooled Rybelsus trials:** 4.2% retinopathy-related adverse reactions vs. 3.8% comparator.[^Rybelsus-label] **Mechanism:** Rapid blood glucose improvement can cause a temporary worsening of retinopathy (early worsening/pseudoregression). Long-term effects on diabetic retinopathy from sustained glycemic control have **not been studied.** **Clinical Recommendation:** Baseline dilated eye exam before initiating semaglutide in all patients with T2DM. Monitor closely if pre-existing diabetic retinopathy present; consider ophthalmology referral. --- ### 4B. NAION (Nonarteritic Anterior Ischemic Optic Neuropathy) — **Major 2025–2026 Safety Update** This is the **most significant new safety signal** since the original semaglutide handout was written. #### What Happened (Timeline) - **2024 (Denmark):** Two major register-based studies identified a signal linking semaglutide use to NAION — a rare eye condition causing sudden, often irreversible partial or complete vision loss in one eye from optic nerve ischemia. - **October 2025:** EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION **is a side effect of semaglutide medicines**, classifying it as **"very rare."** EMA recommended updating product information for Ozempic, Rybelsus, and Wegovy to include NAION.[^EMA-NAION] - **February 2026:** MHRA (UK) issued a Drug Safety Update on NAION risk with semaglutide. Updates to the Summary of Product Characteristics are in progress.[^MHRA-NAION] - **June 2025:** WHO issued a medical product alert, advising health-care professionals and regulatory authorities of the NAION risk; WHO's Advisory Committee on Safety of Medicinal Products concluded the Risk Management Plan for semaglutide should be revised to include NAION as a potential risk.[^WHO-NAION] #### Incidence and Evidence - Classified by EMA as **"very rare"** (i.e., <1 in 10,000 patients). - A prior meta-analysis (Natividade et al., 2025, JAMA Ophthalmology) found OR 3.92 (95% CI 1.02–15.02) for NAION with semaglutide, though it noted insufficient sample sizes and called for larger studies.[^NAION-meta] - Danish register-based data included 28 Danish reports of NAION in semaglutide-treated patients as of May 2025 (15 on Wegovy, 13 on Ozempic/Rybelsus). - Risk factors for NAION independent of drug use include: male sex, age >50, hypertension, diabetes, hyperlipidemia, obstructive sleep apnea, and small optic disc anatomy ("disc at risk"). #### Clinical Recommendation - **Counsel patients** to report any sudden vision loss, eye pain, visual field defects, or optic nerve concerns **immediately**. - If NAION is confirmed, **semaglutide should be stopped.** - Baseline ophthalmology assessment is advisable in patients with multiple NAION risk factors (hypertension, diabetes, age >50, prior optic nerve disease). - Note: US FDA product labels had not been updated to include NAION as of the preparation of this document; monitor for forthcoming US label changes. --- ## 5. ACUTE PANCREATITIS — Rare but Serious ### Evidence In high-cardiovascular-risk T2DM patients (meta-analysis of 3 major RCTs, n=10,013), **acute pancreatitis rate was not significantly different** from placebo (OR 0.92, 95% CI 0.49–1.71).[^Akabane] A large 2025 systematic review (50 trials, n=54,972) similarly found **no significant difference** in serious adverse events between semaglutide and placebo.[^Sillassen2025] Postmarketing reports include **fatal and non-fatal hemorrhagic and necrotizing pancreatitis.**[^Ozempic-label][^Wegovy-label] ### Clinical Recommendation Discontinue semaglutide if pancreatitis is suspected (persistent severe epigastric pain, sometimes radiating to back ± nausea/vomiting, elevated lipase). Do not restart if confirmed. Caution in patients with prior pancreatitis history. --- ## 6. CHOLELITHIASIS (Gallstones) & BILIARY DISEASE ### Incidence In SELECT (Wegovy 2.4 mg, n=17,604, 39.8 months), gallbladder-related disorders were **more frequent with semaglutide (2.8%) vs. placebo (2.3%, p=0.04)**, driven mainly by cholelithiasis (1.4% vs. 1.1%). Cholecystitis rates were similar (0.6% vs. 0.6%).[^Kushner] In Rybelsus trials (14 mg), cholelithiasis was reported in 1% of 7 mg patients; not reported with 14 mg or placebo — though this may reflect shorter trial durations.[^Rybelsus-label] ### Mechanism Delayed gastric emptying and altered bile acid metabolism increase cholesterol saturation and promote gallstone formation. Rapid weight loss itself is an independent gallstone risk factor. ### Clinical Recommendation Evaluate right upper quadrant pain/nausea/fever with ultrasound. Consider cholecystectomy if symptomatic. Baseline ultrasound in patients with prior biliary history or rapid expected weight loss. --- ## 7. ACUTE KIDNEY INJURY (AKI) — Risk and Renal Benefits ### AKI Risk (Indirect, Dehydration-Mediated) AKI is not a direct pharmacological effect of semaglutide. Postmarketing reports link AKI to **volume depletion** from GI-induced nausea/vomiting/diarrhea, sometimes requiring hemodialysis.[^Ozempic-label][^Wegovy-label][^Rybelsus-label] A 2025 FAERS analysis comparing tirzepatide and semaglutide (n=133,872 total reports) found **semaglutide showed a disproportionality signal for AKI** that tirzepatide did not (ROR for tirzepatide vs. semaglutide: 0.44, 95% CI 0.38–0.50), though causality cannot be confirmed and reporting bias exists.[^Gandhi] ### Significant Renal Benefit Signal **FLOW Trial (Perkovic et al., 2024, NEJM — injectable semaglutide 1 mg, n=3,533, T2DM + CKD):** The trial was stopped early at prespecified interim analysis after 3.4 years. Semaglutide reduced the risk of the composite kidney endpoint (kidney failure, ≥50% eGFR decline, kidney-related or CV death) by **24% (HR 0.76, 95% CI 0.66–0.88, P=0.0003).** It also reduced: eGFR decline slope by 1.16 mL/min/1.73m² per year, major CV events by 18%, and all-cause mortality by 20%.[^FLOW] → **Ozempic is now FDA-approved for renal endpoints** (reducing sustained eGFR decline, ESRD, and CV death in adults with T2DM and CKD). **SELECT (Wegovy 2.4 mg, non-diabetic obese):** Semaglutide reduced composite kidney endpoint by 22% (HR 0.78, 95% CI 0.63–0.96); eGFR benefit was greatest in those with baseline eGFR <60 mL/min/1.73m² (+2.19 mL/min/1.73m² at 104 weeks).[^Colhoun] ### Clinical Recommendation No dose adjustment is needed for renal impairment. Monitor renal function if significant GI fluid losses occur. Semaglutide represents a **disease-modifying therapy for CKD in T2DM** — the renal benefit substantially outweighs AKI risk in this population when properly monitored. --- ## 8. CARDIOVASCULAR OUTCOMES — Benefits Across All Formulations ### Injectable Semaglutide — SELECT (Wegovy, Non-Diabetic Obese) **SELECT Trial (Lincoff et al., 2023, NEJM; n=17,604, mean follow-up 39.8 months):** In patients with preexisting CVD, overweight/obesity, **without diabetes**: Semaglutide 2.4 mg reduced MACE (CV death, non-fatal MI, non-fatal stroke) by **20%** (HR 0.80, 95% CI 0.72–0.90, P<0.001). Weight loss of **10.2%** was sustained at 208 weeks.[^SELECT][^Ryan-long] → **Wegovy is now FDA-approved for CV risk reduction** in adults with established CVD + overweight/obesity. ### Oral Semaglutide — SOUL Trial (Rybelsus, T2DM + CVD/CKD) **SOUL Trial (McGuire et al., 2025, NEJM; n=9,650, median follow-up 49.5 months):** In patients with T2DM + atherosclerotic CVD and/or CKD: Oral semaglutide 14 mg reduced MACE by **14%** (HR 0.86, 95% CI 0.77–0.96, P=0.006). No increase in serious adverse events (47.9% vs. 50.3% placebo). Oral semaglutide is the **first oral GLP-1 agonist to demonstrate cardiovascular superiority** in a dedicated outcomes trial.[^SOUL] **Consistent class effect confirmed:** A meta-analysis of 10 long-acting GLP-1 RA trials (n=71,351) including SOUL and FLOW found: - MACE: HR 0.86 (−14%) - Hospitalization for heart failure: HR 0.86 (−14%) - Composite kidney outcome: HR 0.83 (−17%) - All-cause mortality: HR 0.88 (−12%) **No significant heterogeneity by route (subcutaneous vs. oral).** Both injectable and oral formulations provide equivalent cardiovascular and renal benefits.[^Lee] ### Heart Rate Ozempic 0.5 mg and 1 mg cause mean heart rate increases of **2–3 beats per minute** in placebo-controlled trials.[^Ozempic-label] No clinically significant arrhythmia increase has been identified. --- ## 9. MENTAL HEALTH AND SUICIDALITY ### Current Evidence The **suicidality concern** raised for semaglutide in earlier regulatory discussions is now well-addressed: **SELECT (n=17,604, 39.8 months):** Suicide/self-injury serious adverse events were **balanced** between groups: 0.11% semaglutide, 0.11% placebo.[^Kushner] **Large systematic review (50 RCTs, n=54,972, Sillassen et al., 2025):** Semaglutide **reduced risk of serious adverse events overall** (RR 0.93, 95% CI 0.88–0.98). No excess suicidality signal identified.[^Sillassen2025] **Real-world evidence** shows no clear increase in risks of depression or self-harm with GLP-1 RAs.[^Thomsen] ### What Changed in US Labels FDA removed a standalone suicidality warning from Wegovy/semaglutide labels in 2024/2025 following review of accumulating evidence that did not support a causal link. Ongoing pharmacovigilance is appropriate, particularly during rapid weight loss phases. ### Positive Mental Health Signals The broader evidence suggests semaglutide may have **favorable effects on quality of life and mental health** in many patients, likely mediated through weight loss and metabolic improvement.[^Weiskirchen] --- ## 10. HYPOGLYCEMIA (With Concurrent Insulin/Sulfonylureas) All three formulations carry this warning. In patients receiving semaglutide in combination with **insulin secretagogues (sulfonylureas) or insulin**, risk of severe hypoglycemia is increased.[^Ozempic-label][^Rybelsus-label][^Wegovy-label] **Key mitigation:** Reduce insulin or sulfonylurea dose when initiating semaglutide. Educate patients on hypoglycemia recognition and management. In monotherapy, severe hypoglycemia rates are similar to placebo.[^Sillassen2025] --- ## 11. PULMONARY ASPIRATION DURING SURGERY/PROCEDURES All three semaglutide formulations now include this warning in the US prescribing label (added during 2024–2025): > _"There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations."_[^Ozempic-label][^Wegovy-label][^Rybelsus-label] **Clinical Recommendation:** - **Instruct all patients on semaglutide** to inform their surgeon, anesthesiologist, and endoscopist before any planned procedure. - Consider modified fasting protocols or temporary drug hold (consult with proceduralist). - Note: FDA acknowledges current data are insufficient to define optimal fasting modification protocols for GLP-1 RA users. --- ## 12. WEIGHT REGAIN AFTER DISCONTINUATION ### Evidence Stopping semaglutide leads to substantial, rapid weight regain. A systematic review and meta-analysis (Berg et al., 2025, 8 RCTs, n=2,372) found that after discontinuing semaglutide/tirzepatide, patients regained a pooled mean of **9.69 kg** (vs. 2.20 kg with liraglutide discontinuation), proportional to the original weight lost.[^Berg] ### Lean Mass After Stopping Preclinical data (Jeromson et al., 2025) showed that lean mass and skeletal muscle recovered to baseline levels after semaglutide discontinuation in matched animal models, suggesting lean mass loss may be **partially reversible** with cessation, though corresponding human data remain limited.[^Jeromson] ### Patient Counseling This is a **chronic, long-term medication** for obesity management. Discuss the relapsing nature of obesity and that weight regain is expected without continuation. Weight loss maintenance requires ongoing therapy plus lifestyle adherence. --- ## 13. FORMULATION COMPARISON: ALL FOUR SEMAGLUTIDE PRODUCTS |Feature|Rybelsus® (oral)|Wegovy® pill (oral)|Ozempic® (injection)|Wegovy® injection| |---|---|---|---|---| |**Indication**|T2DM|Obesity; CV risk|T2DM; CV risk; CKD|Obesity; CV risk; MASH| |**Dose**|3/7/14 mg daily|1.5→25 mg daily|0.5/1/2 mg weekly|0.25→2.4 mg weekly| |**Bioavailability**|~1%|~1%|~89%|~89%| |**GI event rate**|~35%|**~74%**|~30–40%|~56%| |**Weight loss (trial)**|~5% (T2DM doses)|**~14–17%** (OASIS 4)|~5–8% (T2DM doses)|**~13–15%** (STEP 1)| |**CV outcomes trial**|SOUL (+14% MACE)|SELECT (CV indication)|SUSTAIN 6|SELECT (−20% MACE)| |**Fasting protocol**|Yes — 30 min|Yes — 30 min|No|No| |**Refrigeration**|No|**No**|Yes|Yes| |**Pediatric use**|Not approved|Not approved|Not approved|≥12 years| |**MASH indication**|No|No|No|Yes (F2–F3)| |**Self-pay list price**|~$900/month|**~$149–299/month**|~$900/month|~$349–399/month| **Drug interaction note for both oral semaglutide formulations:** Delayed gastric emptying can reduce absorption of co-administered oral medications including levothyroxine, warfarin, oral contraceptives, and narrow-therapeutic-index drugs. Use caution and monitor closely.[^Rybelsus-label][^WegovyPill-dosing] --- ## 13A. WEGOVY® PILL — FOCUSED CLINICAL GUIDE (NEW — December 2025) ### What It Is The **Wegovy® pill (oral semaglutide 25 mg)** was FDA-approved on **December 22, 2025** and launched in US pharmacies in **early January 2026**. It is the first oral GLP-1 receptor agonist approved for chronic weight management in the US — and currently the only oral GLP-1 for obesity worldwide.[^WegovyPill-approval] It uses the same SNAC absorption-enhancing technology as Rybelsus, but at a substantially higher dose ceiling (25 mg vs. 14 mg for Rybelsus), which is what enables obesity-level weight loss. ### FDA-Approved Indications - **Chronic weight management** in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity, used with reduced-calorie diet and physical activity - **Reduction of major adverse cardiovascular events** (CV death, non-fatal MI, non-fatal stroke) in adults with established CVD and overweight/obesity _(CV indication supported by data from SELECT trial + PIONEER PLUS trial, not independently confirmed in oral obesity doses)_[^WegovyPill-approval] **Not yet approved for:** Pediatric patients, MASH, or CKD — these remain injection-only indications. ### Dosing and Escalation |Phase|Dose|Duration| |---|---|---| |Initiation|1.5 mg once daily|4 weeks| |Step 2|4 mg once daily|4 weeks| |Step 3|9 mg once daily|4 weeks| |Maintenance|**25 mg once daily**|Ongoing| Total escalation period: **12 weeks** to reach maintenance dose.[^WegovyPill-dosing] **Administration rules (non-negotiable for efficacy):** - Take in the morning on a completely **empty stomach** - Use **plain water only**, maximum **120 mL (4 oz)** - **Wait ≥30 minutes** before eating, drinking anything else, or taking other oral medications - **Swallow whole** — do not crush, cut, chew, or dissolve - If a dose is missed: skip that day's dose; resume the next scheduled day[^WegovyPill-dosing] ### Efficacy: OASIS 4 Trial (NEJM, September 2025) The pivotal Phase 3 trial (Wharton S, et al., _NEJM_ 2025) that supported FDA approval:[^Wharton][^OASIS4] - **Design:** 71-week, double-blind, RCT; n=307 adults without diabetes; BMI ≥30 or ≥27 with ≥1 comorbidity; 22 sites across 4 countries; 2:1 randomization - **Dose escalation:** 12 weeks (3 mg → 7 mg → 14 mg → 25 mg), then 52-week maintenance - **Population:** 79% women, mean age 48, mean BMI ~35 **Weight loss results at Week 64:** |Outcome|Wegovy pill|Placebo|Difference| |---|---|---|---| |Mean % body weight change (ITT)|**−13.6%**|−2.2%|−11.4 pp (95% CI −13.9 to −9.0, P<0.001)| |Mean % body weight change (on-treatment)|**−16.6%**|−2.7%|—| |≥5% weight loss|**76%**|31%|P<0.001| |≥10% weight loss|significantly higher|—|P<0.001| |≥15% weight loss|significantly higher|—|P<0.001| |≥20% weight loss|**~1 in 3 patients**|—|P<0.001| |Physical function (IWQOL)|significantly improved|—|P<0.001| **Cross-trial comparisons (indirect — not head-to-head):** |Trial|Formulation|Weight loss vs. placebo| |---|---|---| |OASIS 4|Wegovy pill 25 mg daily|−11.4 percentage points| |OASIS 1|Oral semaglutide 50 mg daily|−12.7 percentage points| |STEP 1|Wegovy injection 2.4 mg weekly|−12.4 percentage points| These comparable magnitudes across formulations confirm the Wegovy pill delivers **obesity-grade weight loss equivalent to injectable Wegovy** — without injections.[^WegovyPill-comparison] ### Safety Profile (OASIS 4) The safety profile is **consistent with the known semaglutide GI class effect**, with the notable finding that GI adverse event rates are higher with the daily pill than with weekly injection: - **Any GI adverse event: 74.0%** (semaglutide) vs. 42.2% (placebo) — higher than the ~56% seen with injectable Wegovy in STEP trials[^OASIS4] - Treatment completion rate was 81.5% (semaglutide) vs. 74.5% (placebo) — actually favoring the active arm, indicating GI events were tolerable for most - No new safety signals identified; GI events were predominantly mild-to-moderate and occurred primarily during dose escalation - The full Wegovy boxed warning (thyroid C-cell tumors), contraindications, and class warnings (pancreatitis, gallbladder disease, kidney injury, aspiration risk, NAION, retinopathy) apply equally to the pill formulation ### Unique Practical Advantages of the Pill **1. No refrigeration required.** Unlike injectable Wegovy (and Ozempic), the pill does not require cold-chain storage. This makes it suitable for travel, regions with limited refrigeration infrastructure, and patients for whom storage is a practical barrier.[^OASIS4-context] **2. Needle-free administration.** For patients with needle aversion, skin injection site reactions, or significant anxiety around self-injection, the pill removes a major adherence barrier. **3. Lower self-pay entry cost.** The Wegovy pill launched at **$149/month** for starting doses (1.5 mg and 4 mg) vs. ~$349–399/month for injectable Wegovy — a meaningful cost reduction for self-pay patients.[^WegovyPill-cost] Full retail list price is ~$1,349/month without savings programs. **4. Insurance coverage expanding.** Because the Wegovy pill shares the same brand name and indications as injectable Wegovy, insurance plans that cover injectable Wegovy are generally expected to cover the pill. Patients with commercial insurance may pay as little as $25/month with manufacturer savings programs.[^WegovyPill-cost] ### Key Limitations vs. Injectable Wegovy - **Not approved for pediatric patients** (≥12 years — injection only) - **Not approved for MASH** — liver fibrosis indication remains injection-only (accelerated FDA approval, August 2025) - **Higher GI event burden** (74% vs. ~56% with injection) due to daily dosing - **Strict fasting protocol** creates a non-negotiable daily behavioral demand — missed meals or morning pills taken with coffee may substantially reduce drug absorption - **Drug interaction complexity** — daily dosing means all morning oral co-medications are potentially affected (see Section 13 drug interaction note) - **Long-term data:** OASIS 4 was only 64 weeks (vs. 68 weeks for STEP 1 and 208 weeks of SELECT data for injection). Long-term safety equivalence with injectable Wegovy is assumed based on shared molecule, not yet independently confirmed ### Prescribing Considerations: Who Is the Wegovy Pill Best For? |Patient Profile|Preferred Formulation|Reason| |---|---|---| |Needle-averse adult with obesity|**Wegovy pill**|Equivalent weight loss, no injection| |Obesity + MASH (liver fibrosis F2–F3)|**Wegovy injection**|Only injection approved for MASH| |Obesity in adolescent ≥12 years|**Wegovy injection**|Pill not approved for pediatric use| |Travel-heavy lifestyle, no refrigeration|**Wegovy pill**|No cold-chain needed| |Cannot adhere to daily morning fasting protocol|**Wegovy injection**|Weekly injection has no food restrictions| |Obesity + multiple morning oral medications|**Wegovy injection**|Avoids daily drug interaction concerns| |Self-pay, cost-sensitive|**Wegovy pill**|Lower entry price ($149 vs. $349/month)| --- ## 14. RARE/EMERGING: DRUG ABUSE POTENTIAL & COMPOUNDED SEMAGLUTIDE ### Compounded Semaglutide — Safety Alert The FDA shortage list removal of semaglutide (compounded versions were allowed during the shortage period) means **compounded semaglutide products are no longer legally authorized in the US** for most circumstances as of 2024. Multiple safety concerns with compounded versions include: - Incorrect dosing and concentration errors - Unverified excipients (sodium acetate vs. FDA-approved formulations) - Absent quality manufacturing controls Patients and providers should be counseled to use only FDA-approved branded products.[^GLP1-regulatory] --- ## 15. PREGNANCY AND REPRODUCTIVE CONSIDERATIONS **Discontinue semaglutide when pregnancy is recognized.** Animal studies show fetal malformations and growth reductions at clinically relevant exposures.[^Wegovy-label] Weight loss during pregnancy is not recommended. **Oral contraceptive interaction:** Delayed gastric emptying may reduce absorption of oral hormonal contraceptives. Advise patients to add a barrier method or switch to non-oral contraception during semaglutide use (particularly relevant to Rybelsus and Wegovy during escalation phases).[^StatPearls] **Pediatric use:** Wegovy **injection** is approved for adolescents ≥12 years with obesity (BMI ≥95th percentile). Wegovy **pill**, Ozempic, and Rybelsus safety/efficacy are not established in pediatric patients. **MASH indication (Wegovy injection only):** As of August 15, 2025, Wegovy injection received FDA accelerated approval for **noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis (F2–F3)**. This makes it the first GLP-1 RA approved for a liver disease indication. A confirmatory 240-week outcomes trial (NN9931-4553) is required by December 31, 2029. This indication applies **only to the injectable formulation**, not the pill.[^MASH-approval] --- ## Safety Monitoring Checklist for Long-Term Use |**Domain**|**Baseline Assessment**|**During Therapy**|**Monitoring Frequency**| |---|---|---|---| |**GI Tolerance**|GI history; screen for gastroparesis|Monthly during titration; assess for severe symptoms|Each visit; ED referral if severe dehydration| |**Muscle Mass/Function**|BMI, grip strength in ≥65; body comp if feasible|Counsel resistance exercise + protein intake; functional assessment in elderly|Reassess at 6–12 months in high-risk patients| |**Bone Health**|DEXA if ≥65 or fragility risk factors|Counsel on calcium, vitamin D, weight-bearing exercise|Per standard osteoporosis screening| |**Thyroid**|TSH; assess MEN2/MTC history|Report neck mass, hoarseness, dysphagia|If symptomatic; calcitonin if nodule found| |**Vision (Diabetic Patients)**|Dilated eye exam if T2DM|Ask about vision changes (retinopathy AND NAION)|Annually or if symptomatic| |**Vision (All Patients — NAION)**|Counsel ALL patients to report sudden vision loss|Ask about visual symptoms each visit|Immediately refer if sudden vision loss| |**Gallbladder**|RUQ ultrasound if high risk|Ask about RUQ pain/nausea|As needed| |**Kidney Function**|eGFR, creatinine, UACR|Monitor if GI dehydration events|Annually; urgently if severe GI events| |**Cardiovascular**|BP, HR, EKG if indicated|BP/HR at each visit|Per standard care| |**Hypoglycemia**|Medication reconciliation (insulin, sulfonylurea)|Dose reduce co-agents as needed|Each visit| |**Mental Health**|Screen for depression/suicidality|Ask about mood, behavior|Each visit| |**Surgical Procedures**|Counsel at initiation|Instruct patient to always inform surgical team|Prior to any procedure| |**Oral Rybelsus & Wegovy pill — Drug Interactions**|Review all oral co-medications; note fasting protocol at initiation|Monitor narrow therapeutic-index drugs; remind fasting requirement at each visit|Initiation and dose changes| |**Pregnancy / Contraception**|Confirm contraception method|Counsel to discontinue if pregnant|Each visit for women of reproductive age| --- ## Bottom Line for Patients ✓ **GI symptoms are most common** — nausea, diarrhea, vomiting. Worst during dose escalation, improve over time. Most manageable with slow titration and dietary adjustments. The Wegovy pill has the highest GI rate of all formulations (74%) due to daily dosing — important to set expectations early. ✓ **Muscle loss is real** — roughly 25–45% of weight lost may be lean mass. Resistance exercise and adequate protein (~1.2–1.6 g/kg/day) are essential. Functional muscle strength can still improve even with modest lean mass loss. ✓ **New eye warning (NAION)** — report sudden vision loss immediately. EMA/WHO/MHRA have confirmed this as a very rare but serious risk. Does not apply to diabetic retinopathy — that is a separate concern for diabetic patients. ✓ **Thyroid cancer** — low risk in clinical trials; avoid if personal/family history of MTC or MEN2. Applies to all four formulations. ✓ **Kidney protection** — semaglutide injection now FDA-approved to slow CKD progression in T2DM. Real and meaningful benefit. ✓ **Heart protection** — 14–20% reduction in heart attack, stroke, CV death across both injectable and oral formulations in appropriate populations. ✓ **Surgery/procedures** — always inform your surgical and anesthesia team. Gastric emptying delay can cause aspiration even with fasting. Applies to pill and injection alike. ✓ **Stopping causes weight regain** — on average 9–10 kg returns after discontinuation. This is a long-term medication for a chronic condition. ✓ **Wegovy pill: first oral option for obesity** — approved December 2025, launched January 2026. Comparable weight loss to the injection (~14–17%), no needles, no refrigeration, lower self-pay cost ($149/month starting dose). GI side effects are higher and daily fasting protocol is non-negotiable for it to work. ✓ **Oral semaglutide (Rybelsus AND Wegovy pill) requires strict administration** — empty stomach, ≤120 mL plain water only, 30 minutes before any food or drink. Failure substantially reduces how much drug is absorbed. --- ## Sources and References [^SELECT]: Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. _New England Journal of Medicine_, 1421 citations. [https://consensus.app/papers/details/939c73bd26445b62b367ad8ad8eca016/](https://consensus.app/papers/details/939c73bd26445b62b367ad8ad8eca016/) [^SOUL]: McGuire DK, et al. (2025). Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. _New England Journal of Medicine_, 104 citations. [https://consensus.app/papers/details/33df99a66e635c41b0a35e9ee9e8a514/](https://consensus.app/papers/details/33df99a66e635c41b0a35e9ee9e8a514/) [^FLOW]: Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. _New England Journal of Medicine_, 746 citations. [https://consensus.app/papers/details/9f161a10c5b55f67beca103a60b6f3cf/](https://consensus.app/papers/details/9f161a10c5b55f67beca103a60b6f3cf/) [^Lee]: Lee MMY, et al. (2025). Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral GLP-1 Receptor Agonists in Type 2 Diabetes. _Diabetes Care_, 21 citations. [https://consensus.app/papers/details/bc8c20b7032c5f6bafbed73c4cc33c6a/](https://consensus.app/papers/details/bc8c20b7032c5f6bafbed73c4cc33c6a/) [^Kushner]: Kushner RF, et al. (2025). Safety profile of semaglutide versus placebo in the SELECT study. _Obesity_, 12 citations. [https://consensus.app/papers/details/5fe5a65d183b5fafb8f98c87c478ba43/](https://consensus.app/papers/details/5fe5a65d183b5fafb8f98c87c478ba43/) [^Ryan-long]: Ryan D, et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. _Nature Medicine_, 185 citations. [https://consensus.app/papers/details/14a22137d7ee5dec972872f236bbb87f/](https://consensus.app/papers/details/14a22137d7ee5dec972872f236bbb87f/) [^Colhoun]: Colhoun H, et al. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. _Nature Medicine_, 129 citations. [https://consensus.app/papers/details/f334dbe69caa59bcb7bdb89b8d6d0121/](https://consensus.app/papers/details/f334dbe69caa59bcb7bdb89b8d6d0121/) [^Sillassen2025]: Sillassen C, et al. (2025). The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis. _BMC Medicine_, 50 trials, n=54,972. [https://consensus.app/papers/details/7dc78dd11e005262998c025af7fd85ea/](https://consensus.app/papers/details/7dc78dd11e005262998c025af7fd85ea/) [^Akabane]: Akabane MAC, et al. (2024). Effects of Semaglutide on Safety Outcomes in T2DM and High CV Risk: Meta-analysis. _Circulation_. [https://consensus.app/papers/details/7c18c98426ce53c98dbc5ee3e997e2af/](https://consensus.app/papers/details/7c18c98426ce53c98dbc5ee3e997e2af/) [^Feier]: Feier CVI, et al. (2024). Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic): A Systematic Literature Review. _International Journal of Molecular Sciences_, 39 citations. [https://consensus.app/papers/details/4daa9ae75e985b8ebba8a5893944f40d/](https://consensus.app/papers/details/4daa9ae75e985b8ebba8a5893944f40d/) [^Thomsen]: Thomsen R, et al. (2025). Real-world evidence on utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. _Diabetes, Obesity & Metabolism_, 55 citations. [https://consensus.app/papers/details/49819fd7115354c1b29028153d1ba4ef/](https://consensus.app/papers/details/49819fd7115354c1b29028153d1ba4ef/) [^Weiskirchen]: Weiskirchen R, et al. (2025). How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense? _British Journal of Pharmacology_, 14 citations. [https://consensus.app/papers/details/7c36ad6033bf5cdea5b43e64435af79a/](https://consensus.app/papers/details/7c36ad6033bf5cdea5b43e64435af79a/) [^Gandhi]: Gandhi A, et al. (2025). Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS) Disproportionality Study. _Journal of Clinical Medicine_. [https://consensus.app/papers/details/0225f92e10d45bbd96975ca53fcd6160/](https://consensus.app/papers/details/0225f92e10d45bbd96975ca53fcd6160/) [^Berg]: Berg S, et al. (2025). Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. _Obesity Reviews_, 29 citations. [https://consensus.app/papers/details/2b1d006ca38f5903a90bb55b5cc257b7/](https://consensus.app/papers/details/2b1d006ca38f5903a90bb55b5cc257b7/) [^SEMALEAN]: Alissou M, et al. (2025). Impact of Semaglutide on fat mass, lean mass and muscle function: The SEMALEAN study. _Diabetes, Obesity & Metabolism_, 5 citations. [https://consensus.app/papers/details/c2dd4dd6117d5289a99f61d604de1e83/](https://consensus.app/papers/details/c2dd4dd6117d5289a99f61d604de1e83/) [^Karakasis]: Karakasis P, et al. (2024). Effect of GLP-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. _Metabolism_, 76 citations. [https://consensus.app/papers/details/4ecac8e6635e55b0a0240a60087daba4/](https://consensus.app/papers/details/4ecac8e6635e55b0a0240a60087daba4/) [^Ryan]: Ryan DH. (2025). New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? _Reviews in Endocrine & Metabolic Disorders_, 14 citations. [https://consensus.app/papers/details/083498137cfe5f19bce5ddd3869fb097/](https://consensus.app/papers/details/083498137cfe5f19bce5ddd3869fb097/) [^Neeland]: Neeland I, et al. (2024). Changes in lean body mass with GLP-1-based therapies and mitigation strategies. _Diabetes_, 164 citations. [https://consensus.app/papers/details/e539a7b1f3c35174a282bedbdfa51fd4/](https://consensus.app/papers/details/e539a7b1f3c35174a282bedbdfa51fd4/) [^Linge]: Linge J, et al. (2024). Muscle Mass and GLP-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? _Circulation_, 58 citations. [https://consensus.app/papers/details/6f650d34e4295ad9939c9f6658cb1a22/](https://consensus.app/papers/details/6f650d34e4295ad9939c9f6658cb1a22/) [^Locatelli]: Locatelli JC, et al. (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? _Diabetes Care_, 78 citations. [https://consensus.app/papers/details/c5f7dcfa805c5b878c0d3eb5f0055445/](https://consensus.app/papers/details/c5f7dcfa805c5b878c0d3eb5f0055445/) [^Chavez]: Chavez AM, et al. (2025). Nutrition support whilst on GLP-1 based therapy. Is it necessary? _Current Opinion in Clinical Nutrition and Metabolic Care_, 8 citations. [https://consensus.app/papers/details/8ae5f3a9a18a526196bd15adec841a13/](https://consensus.app/papers/details/8ae5f3a9a18a526196bd15adec841a13/) [^Stefanakis]: Stefanakis K, et al. (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. _Metabolism_, 70 citations. [https://consensus.app/papers/details/b1a4c051f3535d468ea9d543c52459a6/](https://consensus.app/papers/details/b1a4c051f3535d468ea9d543c52459a6/) [^Nunn]: Nunn E, et al. (2024). Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. _Molecular Metabolism_, 69 citations. [https://consensus.app/papers/details/3b4a5cbbaa985f2b8b3f9a0c36d578aa/](https://consensus.app/papers/details/3b4a5cbbaa985f2b8b3f9a0c36d578aa/) [^Jeromson]: Jeromson S, et al. (2025). Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity. _Journal of Physiology_. [https://consensus.app/papers/details/aadab44e59bf5f7a99e20763db7bf413/](https://consensus.app/papers/details/aadab44e59bf5f7a99e20763db7bf413/) [^Chun]: Chun E, et al. (2025). Weight loss and body composition after compounded semaglutide treatment in a real-world setting. _Diabetes_, 7 citations. [https://consensus.app/papers/details/04c406c4fee65926b5a7a6d7416bec5c/](https://consensus.app/papers/details/04c406c4fee65926b5a7a6d7416bec5c/) [^Nelson]: Nelson LW, et al. (2024). Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide Therapy. _AJR American Journal of Roentgenology_, 10 citations. [https://consensus.app/papers/details/00d3d017940d5be4a52d4487030a3fff/](https://consensus.app/papers/details/00d3d017940d5be4a52d4487030a3fff/) [^Chen]: Chen AS, et al. (2025). Treating Sarcopenic Obesity in the Era of Incretin Therapies. _Diabetes_, 9 citations. [https://consensus.app/papers/details/8dd3969f8a02592791bc437d34c952a2/](https://consensus.app/papers/details/8dd3969f8a02592791bc437d34c952a2/) [^NAION-meta]: Natividade GR, et al. (2025). Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. _JAMA Ophthalmology_, 5 citations. [https://consensus.app/papers/details/09d0933daeda58cea527ab084a587a45/](https://consensus.app/papers/details/09d0933daeda58cea527ab084a587a45/) [^EMA-NAION]: EMA/PRAC. (October 2025). PRAC concludes NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. [https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy](https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) [^MHRA-NAION]: MHRA Drug Safety Update. (February 2026). Semaglutide (Wegovy, Ozempic, Rybelsus): Risk of NAION. [https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion](https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion) [^WHO-NAION]: WHO Medical Product Alert. (June 27, 2025). Semaglutide medicines and risk of NAION. [https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion](https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion) [^GLP1-regulatory]: GLP-1 Regulatory Updates, Approvals and Label Changes (2026). [https://defectivedrugsite.com/glp-1-drugs/lawsuits/regulatory-updates/](https://defectivedrugsite.com/glp-1-drugs/lawsuits/regulatory-updates/) [^StatPearls]: StatPearls. Semaglutide. NCBI Bookshelf. [https://www.ncbi.nlm.nih.gov/books/NBK603723/](https://www.ncbi.nlm.nih.gov/books/NBK603723/) [^Ozempic-label]: FDA Prescribing Information. OZEMPIC (semaglutide) Injection. Revised January 2025. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf) [^Wegovy-label]: FDA Prescribing Information. WEGOVY (semaglutide) Injection. Revised November 2024. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s021lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s021lbl.pdf) [^Rybelsus-label]: FDA Prescribing Information. RYBELSUS (semaglutide) Tablets. Revised October 2025. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf) [^WegovyPill-approval]: Novo Nordisk. (December 22, 2025). Wegovy® pill approved in the US as first oral GLP-1 for weight management. [https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916472](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916472) [^Wharton]: Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity — OASIS 4. _New England Journal of Medicine_. DOI: 10.1056/NEJMoa2500969. [https://pubmed.ncbi.nlm.nih.gov/40934115/](https://pubmed.ncbi.nlm.nih.gov/40934115/) [^OASIS4]: Garvey W, et al. (2024). Efficacy and safety of oral semaglutide 25 mg in adults with overweight/obesity: The OASIS 4 RCT. Oral presentation, ObesityWeek® 2024. Novo Nordisk ScienceHub. [https://sciencehub.novonordisk.com/content/dam/sciencehub/global/en/congresses-and-scientific-publications/congresses/ow2024/Garvey/documents/Garvey_OASIS_4_OW24-oral_Final_23Oct24.pdf](https://sciencehub.novonordisk.com/content/dam/sciencehub/global/en/congresses-and-scientific-publications/congresses/ow2024/Garvey/documents/Garvey_OASIS_4_OW24-oral_Final_23Oct24.pdf) [^WegovyPill-dosing]: Wegovy® Pill Guide and Dosing Information. Novo Nordisk. [https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html](https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html) [^WegovyPill-cost]: NovoCare® Wegovy® Cost & Coverage. Novo Nordisk. [https://www.novocare.com/patient/medicines/wegovy/check-coverage.html](https://www.novocare.com/patient/medicines/wegovy/check-coverage.html) [^WegovyPill-comparison]: Oral Semaglutide Wegovy Pill vs Injection Guide. hlbenefits.com, 2026. [https://www.hlbenefits.com/oral-semaglutide-rybelsus-wegovy-pill](https://www.hlbenefits.com/oral-semaglutide-rybelsus-wegovy-pill) [^OASIS4-context]: Novo Nordisk OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management. _Endocrine News_, February 2026. [https://endocrinenews.endocrine.org/novo-nordisks-oasis-4-study-validates-daily-oral-pill-for-chronic-weight-management/](https://endocrinenews.endocrine.org/novo-nordisks-oasis-4-study-validates-daily-oral-pill-for-chronic-weight-management/) [^MASH-approval]: FDA Accelerated Approval — Wegovy® (semaglutide) for MASH with liver fibrosis (F2–F3). Approved August 15, 2025. PMR NN9931-4553 confirmatory trial required by December 31, 2029. [http://www.fda.gov/drugs/accelerated-approval-program/ongoing-non-malignant-hematology-neurological-disorders-and-other-indications-accelerated-approvals](http://www.fda.gov/drugs/accelerated-approval-program/ongoing-non-malignant-hematology-neurological-disorders-and-other-indications-accelerated-approvals) --- ## Document Information - **Created:** May 2026 - **Format:** Markdown with complete citation footnotes - **Formulations Covered:** Ozempic® (injectable, T2DM/CV/CKD), Wegovy® injection (obesity/CV/MASH/pediatric), Wegovy® pill (oral obesity/CV — FDA approved December 2025), Rybelsus® (oral, T2DM/CV) - **Intended Audience:** Healthcare providers, patients, clinical educators - **Evidence Quality:** Landmark RCTs (SELECT, FLOW, SOUL, SUSTAIN 6, PIONEER 6, OASIS 4), FDA prescribing labels (2024–2026), EMA/WHO/MHRA safety communications (2025–2026), systematic reviews and meta-analyses (2023–2026) - **Disclaimer:** This document is for informational purposes and should not replace clinical judgment or direct patient consultation.